CreatorsPublishersAdvertisers
View more in
Diseases & Treatments

Melflufen/Dexamethasone Demonstrates Superiority vs Pomalidomide in Transplant-Naïve Relapsed/Refractory Multiple Myeloma

cancernetwork.com
 2021-09-11

Cover picture for the articleThe combination of melflufen plus dexamethasone produced a progression-free survival benefit over pomalidomide plus dexamethasone in patients with transplant-naïve relapsed/refractory multiple myeloma. Melphalan flufenamide (melflufen) and dexamethasone produced superior a progression-free survival (PFS) benefit compared with pomalidomide plus dexamethasone for patients with transplant-naïve relapsed/refractory multiple myeloma, according to the results...

www.cancernetwork.com

Comments / 0

Comments / 0